Alpha Tau Medical Ltd., a company established in Israel in November 2015. The Company is a clinical-stage oncology company focused on local radiotherapy for solid tumors utilizing innate relative bioavailability and short-course α granules. The company's proprietary Alpha DaRT technology is designed to take advantage of the specific therapeutic properties of alpha particles, while aiming to overcome or even exploit the traditional disadvantages of limited range of alpha radiation for potential benefits. The company has conducted several clinical trials in clinical sites around the world to evaluate and continue to evaluate the feasibility, safety and efficacy of Alpha DaRT technology in the treatment of superficial lesions, namely skin, head or neck tumors. 

Expected P&L on Expiry

Key Stats

Pricing Model

About DRTS20260918C20